Abstract
Rationale α-ET (α-ethyltryptamine), a homolog of the classical hallucinogen α-methyltryptamine, was once prescribed clinically as an antidepressant. Classical psychedelic drugs are currently of interest as potential pharmacotherapy for psychiatric disorders. Objectives Drug discrimination was used to (a) determine if α-ET-like stimulus effects could be engendered by the prototypical phenylalkylamines MDMA (“Ecstasy”) or MDA (“Love Drug”) and (b) evaluate the α-ET-like stimulus effects of four synthesized aryl-substituted monomethoxy analogs of α-ET (4-OMe-, 5-OMe-, 6-OMe- and 7-OMe-α-ET). Methods Rats were trained to discriminate α-ET (2.5 mg/kg) from saline using a two-lever operant task. Results The α-ET (ED50 = 1.04 mg/kg) stimulus generalized to MDMA (ED50 = 0.72 mg/kg) and MDA (ED50 = 0.48 mg/kg). The four α-ET derivatives produced various results; 4-OMe α-ET yielded negligible (20% maximum) α-ET-like responding; 5-OMe α-ET occasioned a modest level (40% maximum) of α-ET-like substitution; 6-OMe α-ET (ED50 = 6.26 mg/kg) generalized completely, but in a narrow dose range and in an inverted U-shaped manner; 7-OMe α-ET (ED50 = 2.78 mg/kg) generalized completely. Conclusions α-ET stimulus effects are similar to those of MDMA, but appear more closely aligned to those of MDA and are produced by its stereoisomers which, when combined, exert MDA/MDMA-, hallucinogen- and some stimulant-like stimulus actions. Thus, α-ET exerts a complex (compound) stimulus and appears to be a tryptamine counterpart of these prototypic phenylalkylamines. The monomethoxy analogs of α-ET produced an assortment of α-ET-like outcomes such that future investigations of these agents will likely need to be performed on an individual basis; extrapolations of α-ET-like effects to these analogs should be done judiciously.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Allegra S, Chiara F, Di Grazia D, Gaspari M, Silvia De Francia S (2023) Evaluation of sex differences in preclinical pharmacology research: how far is left to go? Pharmaceuticals 16:786–804. https://doi.org/10.3390/ph16060786
Andersen KAA, Carhart-Harris R, Nutt DJ, Erritzoe D (2021) Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. Acta Psychiatr Scand 143:101–118. https://doi.org/10.1111/acps.13249
Anthony WC (1970) Antidepressant compositions and methods using α-ethyltryptamine. U.S. Patent 3,531,573. September 29, 1970
Anthony WC (1972) Upjohn Co. Assignee, d- and l-α-Ethyltryptamine acetates. Patent: Ger. Offen. (1972), DE 2034000 A 19720120
Araújo AM, Carvalho F, de Lourdes Bastos M, Guedes de Pinho P, Carvalho M (2015) The hallucinogenic world of tryptamines: An updated review. Arch Toxicol 89:1151–1173. https://doi.org/10.1007/s00204-015-1513-x
Ask AL, Hellström W, Norrman S, Ogren SO, Ross SB (1982) Selective inhibition of the A form of monoamine oxidase by 4-dimethylamino-alpha-methylphenylalkylamine derivatives in the rat. Neuropharmacology 21:299–308. https://doi.org/10.1016/0028-3908(82)90092-2
Ask AL, Fagervall I, Huang RB, Ross RB SB (1989) Release of 3H-5-hydroxytryptamine by amiflamine and related phenylalkylamines from rat occipital cortex slices. Naunyn Schmiedebergs Arch Pharmacol 339:684–689. https://doi.org/10.1007/BF00168662
Baker GB, Hiob LE, Martin IL, Mitchell PR, Dewhurst WG (1980) Interactions of tryptamine analogs with 5-hydroxytryptamine and dopamine in rat striatum in vitro. Proc West Pharmacol Soc 23:167–170
Berquist MD, Fantegrossi WE (2018) Discriminative Stimulus Effects of Psychostimulants. Curr Top Behav Neurosci 39:29–49. https://doi.org/10.1007/7854_2017_5
Blough BE, Landavazo A, Partilla JS, Decker AM, Page KM, Baumann MH, Rothman RB (2014) Alpha-ethyltryptamines as dual dopamine-serotonin releasers. Bioorg Med Chem Lett 24:4754–4758. https://doi.org/10.1016/j.bmcl.2014.07.062
Colombo G, Agabio R, Lobina C, Reali R, Fadda F, Gessa GL (1995) Symmetrical generalization between the discriminative stimulus effects of gamma-hydroxybutyric acid and ethanol: occurrence within narrow dose ranges. Physiol Behav 57:105–111. https://doi.org/10.1016/0031-9384(94)00215-q
Federal Register (1994) Schedules of controlled substances; placement of alpha-ethyltryptamine into Schedule I. Federal Register, vol. 59, issue 175, pp 46757–46759, Washington, D. C
Federal Register (1993) Schedules of controlled substances; temporary placement of alpha-ethyltryptamine into Schedule I. Federal Register, vol. 58, No. 47, pp 13533–13534, Washington, D. C
Finney D (1952) Probit analysis. Cambridge University Press, London, UK
Gessner PK (1970) In: Psychotomimetic Drugs, Efron DH (ed), Raven, New York, pp 105–122
Gessner PK, Godse DD, Krull AH, McMullan JM (1968) Structure-activity relationships among 5-methoxy-N,N-dimethyltryptamine, 4-hydroxy-N,N-dimethyltryptamine (psilocin) and other substituted tryptamines. Life Sci 7:267–277. https://doi.org/10.1016/0024-3205(68)90200-2
Glennon RA (1993) MDMA-like stimulus effects of alpha-ethyltryptamine and the alpha-ethyl homolog of DOM. Pharmacol Biochem Behav 46:459–462. https://doi.org/10.1016/0091-3057(93)90379-8
Glennon RA, Dukat MG (2023) α-Ethyltryptamine: A Ratiocinatory Review of a Forgotten Antidepressant. ACS Pharmacol Transl Sci 6:1780–1789. https://doi.org/10.1021/acsptsci.3c00139
Glennon RA, Higgs R (1992) Investigation of MDMA-related agents in rats trained to discriminate MDMA from saline. Pharmacol Biochem Behav 43:759–763. https://doi.org/10.1016/0091-3057(92)90405-5
Glennon RA, Young R (1984) MDA: a psychoactive agent with dual stimulus effects. Life Sci 34:379–383. https://doi.org/10.1016/0024-3205(84)90627-1
Glennon RA, Young R (2011a) Chap. 6 Drug discrimination and mechanisms of drug action. Drug Discrimination: Applications to Medicinal Chemistry and Drug Studies. John Wiley & Sons, Inc., Hoboken, New Jersey, pp 183–216
Glennon RA, Young R (2011b) Chap. 3 Drug discrimination: Practical considerations. Drug Discrimination: Applications to Medicinal Chemistry and Drug Studies. John Wiley & Sons, Inc., Hoboken, New Jersey, pp 41–128
Glennon RA, Young R (2011c) Chap. 4 Role of stereochemistry in drug discrimination studies. Drug Discrimination: Applications to Medicinal Chemistry and Drug Studies. John Wiley & Sons, Inc., Hoboken, New Jersey, pp 129–161
Glennon RA, Young R, Rosecrans JA, Kallman MJ (1980) Hallucinogenic agents as discriminative stimuli: a correlation with serotonin receptor affinities. Psychopharmacology 68:155–158. https://doi.org/10.1007/BF00432133
Glennon RA, Young R, Rosecrans JA, Anderson GM (1982a) Discriminative stimulus properties of MDA analogs. Biol Psychiatry 17:807–814
Glennon RA, Young R, Benington F, Morin RD (1982b) Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane. J Med Chem 2510:1163–1168. https://doi.org/10.1021/jm00352a013
Glennon RA, Young R, Jacyno JM (1983a) Indolealkylamine and phenalkylamine hallucinogens. Effect of alpha-methyl and N-methyl substituents on behavioral activity. Biochem Pharmacol 32:1267–1273. https://doi.org/10.1016/0006-2952(83)90281-2
Glennon RA, Young R, Jacyno JM, Slusher M, Rosecrans JA (1983b) DOM-stimulus generalization to LSD and other hallucinogenic indolealkylamines. Eur J Pharmacol 86:453–459. https://doi.org/10.1016/0014-2999(83)90196-6
Glennon RA, Young R, Hauck AE (1985) Structure-activity studies on methoxy-substituted phenylisopropylamines using drug discrimination methodology. Pharmacol Biochem Behav 22:723–729. https://doi.org/10.1016/0091-3057(85)90520-9
Glennon RA, Higgs R, Young R, Issa H (1992) Further studies on N-methyl-1(3,4-methylenedioxyphenyl)-2-aminopropane as a discriminative stimulus: antagonism by 5-hydroxytryptamine3 antagonists. Pharmacol Biochem Behav 43:1099–1106. https://doi.org/10.1016/0091-3057(92)90488-2
Glennon RA, Bondareva T, Young R (2006) alpha-Ethyltryptamine (alpha-ET) as a discriminative stimulus in rats. Pharmacol Biochem Behav 85:448–453. https://doi.org/10.1016/j.pbb.2006.09.014
Govier WM, Howes BG, Gibbons AJ (1953) The oxidative deamination of serotonin and other 3-(beta-aminoethyl)-indoles by monamine oxidase and the effect of these compounds on the deamination of tyramine. Science 118:596–597. https://doi.org/10.1126/science.118.3072.596
Gray JE, McWade DH, Johnston RL, Larson EJ, Freyburger WA (1962) Toxicopathologic studies of alpha-methyl- and alpha-ethyltryptamine acetates (Monase). I. Acute, subacute, and miscellaneous studies. Toxicol Appl Pharmacol 4:547–560. https://doi.org/10.1016/0041-008x(62)90083-2
Greig ME, Walk RA, Gibbons AJ (1959) The effect of three tryptamine derivatives on serotonin metabolism in vitro and in vivo. J Pharmacol Exp Ther 127:110–115
Hester JB, Greig ME, Anthony WC, Heinzelman RV, Szmuszkovicz J (1964) Enzyme inhibitory activity of 3-(2-aminobutyl) indole derivatives. J Med Chem 7:274–279. https://doi.org/10.1021/jm00333a006
Hong SS, Young R, Glennon RA (2001) Discriminative stimulus properties of alpha-ethyltryptamine optical isomers. Pharmacol Biochem Behav 70:311–316. https://doi.org/10.1016/s0091-3057(01)00605-0
Huang XM, Johnson MP, Nichols DE (1991) Reduction in brain serotonin markers by alpha-ethyltryptamine (Monase). Eur J Pharmacol 200:187–190. https://doi.org/10.1016/0014-2999(91)90686-k
Huang X, Marona-Lewicka D, Nichols DE (1992) -methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent. Eur J Pharmacol 229:31–38. https://doi.org/10.1016/0014-2999(92)90282-9. p
Johnson MP, Huang XM, Oberlender R, Nash JF, Nichols DE (1990) Behavioral, biochemical and neurotoxicological actions of the alpha-ethyl homologue of p-chloroamphetamine. Eur J Pharmacol 191:1–10. https://doi.org/10.1016/0014-2999(90)94090-k
Kamien JB, Bickel WK, Hughes JR, Higgins ST, Smith BJ (1993) Drug discrimination by humans compared to nonhumans: current status and future directions. Psychopharmacology 111:259–270. https://doi.org/10.1007/BF02244940
Khorana N, Young R, Glennon RA (2009) Effect of 8-hydroxy-2-(N,N-di-n-propylamino)tetralin and MDMA on the discriminative stimulus effects of the classical hallucinogen DOM in rats. Pharmacol Biochem Behav 91:385–392. https://doi.org/10.1016/j.pbb.2008.08.013
Khorana N, Pullagurla MR, Dukat M, Young R, Glennon RA (2004) Stimulus effects of three sulfur-containing psychoactive agents. Pharmacol Biochem Behav 78:821–826. https://doi.org/10.1016/j.pbb.2004.05.021
Krebs KM, Geyer MA (1993) Behavioral characterization of alpha-ethyltryptamine, a tryptamine derivative with MDMA-like properties in rats. Psychopharmacology 113:284–287. https://doi.org/10.1007/BF02245712
Lessin AW, Long RF, Parkes MW MW (1967) The central stimulant properties of some substituted indolylalkylamines and βeta-carbolines and their activities as inhibitors of monoamine oxidase and the uptake of 5-hydroxytryptamine. Br J Pharmacol Chemother 29:70–79. https://doi.org/10.1111/j.1476-5381.1967.tb01940.x
Marquardt GM, DiStefano V, Ling LL (1978) Pharmacological effects of (±)-, (S)-, and (R)-MDA. In: Stillman RC, Willette RE (eds) The Psychopharmacology of Hallucinogens. Pergamon, New York, pp 84–104
Martinez DL, Geyer MA (1997) Characterization of the disruptions of prepulse inhibition and habituation of startle induced by alpha-ethyltryptamine. Neuropsychopharmacology 16:246–255. https://doi.org/10.1016/S0893-133X(96)00240-0
Matthews RJ, Roberts BJ, Adkins PK (1961) Neuropharmacological studies on DL-alpha-ethyltryptamine acetate. J Neuropsychiatr 2:151–158
Murphree HB, Dippy RH, Jenny EH, Pfeiffer CC (1961) Effects in normal man of alpha-methyltryptamine and alpha-ethyltryptamine. Clin Pharmacol Ther 2:722–726. https://doi.org/10.1002/cpt196126722
National Research Council (2011) Guide for the care and use of laboratory animals (8th ed.). Washington, DC: National Academies Press; 2011
Nichols DE, Walter H (2021) The History of Psychedelics in Psychiatry. Pharmacopsychiatry 54:151–166. https://doi.org/10.1055/a-1310-3990
Nichols DE, Lloyd DH, Johnson MP, Hoffman AJ (1988) Synthesis and serotonin receptor affinities of a series of enantiomers of α-methyltryptamines: evidence for the binding conformation of tryptamines at serotonin 5-HT1B receptors. J Med Chem 31:1406–1412. https://doi.org/10.1021/jm00402a026
Nutt D, Erritzoe D, Carhart-Harris R (2020) Psychedelic Psychiatry’s Brave New World. Cell 181:24–28
Poschel BP, Ninteman FW (1964) Excitatory (Antidepressant?) effects of monoamine oxidase inhibitors on the reward system of the brain. Life Sci 3:903–910. https://doi.org/10.1016/0024-3205(64)90155-9
Pscheidt GR (1963) Anomalous actions of monoamine oxidase inhibitors. Ann N Y Acad Sci 107:1057–1067. https://doi.org/10.1111/j.1749-6632.1963.tb13349.x
Rényi L, Ross SB (1985) Effects of amiflamine and related compounds on the accumulation of biogenic monoamines in rat brain slices in vitro and ex vivo in relation to their behavioural effects. Acta Pharmacol Toxicol 56:416–426. https://doi.org/10.1111/j.1600-0773.1985.tb01312.x
Rosecrans JA, Young R (2018) Discriminative Stimulus Properties of S(-)-Nicotine: A Drug for All Seasons. Curr Top Behav Neurosci 39:51–94. https://doi.org/10.1007/7854_2017_3
Roth BL, Gumpper RH (2023) Psychedelics as Transformative Therapeutics. Am J Psychiatry 180:340–347. https://doi.org/10.1176/appi.ajp.20230172
Rush CR, Vansickel AR, Stoops WW (2011) Human drug discrimination: Methodological considerations and application to elucidating the neuropharmacology of amphetamines. Drug Discrimination: Applications to Medicinal Chemistry and Drug Studies. John Wiley & Sons, Inc., Hoboken, New Jersey, pp 431–461
Schechter MD (1998) MDMA-like Stimulus effects of hallucinogens in male fawn-hooded rats. Pharmacol Biochem Behav 59:265–270. https://doi.org/10.1016/s0091-3057(97)00415-2
Shadani S, Conn K, Andrews ZB, Foldi CJ (2024) Potential differences in psychedelic actions based on biological sex. Endocrinology 165:bqae083. https://doi.org/10.1210/endocr/bqae083
Shulgin AT (1978) Psychotomimetic drugs: Structure-activity relationships. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of psychopharmacology, vol 11. Plenum, New York, pp 243–333
Shulgin AT (2003) Basic Pharmacology and Effects. In: Laing R, Siegel JA (eds) Hallucinogens. A Forensic Drug Handbook. Academic, London, pp 67–137
Shulgin A, Shulgin A (1991) Pihkal. Berkeley, CA: Transform Press, 1991, pp 714–719
Shulgin A, Shulgin A (1997a) TiHKAL (Tryptamines i Have Known And Loved): The Continuation. Transform, Berkeley, CA
Shulgin A, Shulgin A (1997b) #11, a-ET: Alpha-Ethyltryptamine; Indole,3-(2-Aminobutyl); Tryptamine, Alpha-Ethyl; 3-(2-Aminobutyl) Indole; Monase,. TiHKAL (Tryptamines i Have Known And Loved): The Continuation pp 433–441
Sing KP, Gautam SK (1977) A study of antidepressant activity of some indole alkylamines. Arzneimittelforschung 27:2002–2005
Steiner WG, Pscheidt GR, Costa E, Himwich HE (1963) Alpha-ethyltryptamine (Etryptamine): an electroencephalographic, behavioral and neurochemical analysis. Psychopharmacologia 4:354–366. https://doi.org/10.1007/BF00405246
United States of America, Plaintiff S, Forbes D et al (1992a) Court: United States District Court, D. Colorado, Date published: Nov 20, 1992 cite as (U.S. v. Forbes) United States v. Forbes, 806 F. Supp. 232 (D. Colo. 1992)
United States of America, Plaintiff, v. Damon S. Forbes, et al., Defendants (1992b) District Court for the District of Colorado – 806 F (1992b) Supp. 232 (D. Colo. 1992) November 20, 1992 cite as. U.S. v. Forbes
Upjohn Co (1972) Assignee, French Patent FR 2097052. Resolution of α-ethyltryptamine. Fr. Demande (Mar 03, 1972), FR 2097052, A5 19720303
Winger G, Woolverton WL, Rowlett JK, English JA, Patrick GA, Nader MA, McDaniel RE, Hawkins WT, Massey BW, Harris LS, Woods JH (1994) Progress report from the testing program for stimulant and depressant drugs 1994. In: Harris LS, editor. Problems of drug dependence 1994: 56th annual scientific meeting, The College on Problems of Drug Dependence, Inc., NIDA Research Monograph 152, pp 105–116
Winstock AR, Kaar S, Borschmann R (2014) Dimethyltryptamine (DMT): Prevalence, user characteristics and abuse liability in a large global sample. J Psychopharmacol 28:49–54. https://doi.org/10.1177/0269881113513852
Young R (2009) Drug Discrimination. In: Buccafusco JJ, editor. Methods of Behavior Analysis in Neuroscience. 2nd edition. Boca Raton (FL): CRC Press/Taylor & Francis; 2009. Chapter 3. pp 39–58
Young R, Glennon RA (1986) Discriminative stimulus properties of amphetamine and structurally related phenalkylamines. Med Res Rev 6:99–130. https://doi.org/10.1002/med.2610060105
Young R, Glennon RA (1987) Stimulus properties of benzodiazepines: correlations with binding affinities, therapeutic potency, and structure activity relationships (SAR). Psychopharmacology 93:529–533. https://doi.org/10.1007/BF00207248
Young R, Glennon RA (1996) A three-lever operant procedure differentiates the stimulus effects of R(-)-MDA from S(+)-MDA. J Pharmacol Exp Ther 276:594–601
Young R, Hong S, Glennon RA (1995) α-ET: A tryptamine version of MDA? NIDA Res Monogr 162:357
Young R, Khorana N, Bondareva T, Glennon RA (2005) Pizotyline effectively attenuates the stimulus effects of N-methyl-3,4-methylenedioxyamphetamine (MDMA). Pharmacol Biochem Behav 82:404–410. https://doi.org/10.1016/j.pbb.2005.09.010
Funding
Supported, in part, by National Institute on Drug Abuse (NIDA) grant DA-01642.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical statement
The research reported here was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at Virginia Commonwealth University and is in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council 2011).
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Abate, C., Young, R., Dukat, M. et al. Discriminative stimulus properties of α-ethyltryptamine (α-ET) in rats: α-ET-like effects of MDMA, MDA and aryl-monomethoxy substituted derivatives of α-ET. Psychopharmacology 242, 1407–1418 (2025). https://doi.org/10.1007/s00213-024-06738-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-024-06738-y